Inogen (INGN) Q2 2026 Earnings Call Transcript
Inogen (INGN) reported Q2 2026 revenue of $95.1 million, up 3% year over year, driven by international sales of $41.3 million (+14.8%) and new product contributions. U.S. sales were $42.3 million, down 2.3%. Adjusted EBITDA was $2.4 million (+15.2%). Full-year revenue guidance was cut to $355-$361 million; adjusted EBITDA guidance is about $4 million. Cash was $106.8 million with zero debt.
How this was made
The 30-second read
Why it matters
The key tradable items are the full-year revenue guidance reduction and the raised adjusted EBITDA guidance, both tied to operational leverage and channel/distributor dynamics.
Market read
Traders can reprice INGN based on the combination of a revenue guidance cut and an adjusted EBITDA guidance raise, plus quantified Q2 segment trends.
What to watch
Rental patients declined to 45,500 and U.S. rentals fell 11.8%, which could pressure future recurring revenue even if gross margin improves.
Background
Inogen’s Q2 2026 call focused on international growth, new product contributions (Voxi, CPAP mask expansion), and a U.S. channel mix shift away from DTC.
Ticker impact
Inogen reported Q2 revenue of $95.1M and cut full-year revenue guidance to $355M-$361M due to U.S. channel mix pressure.
Likely choppy near-term trading as investors weigh lower top-line outlook against improved profitability guidance.
The article provides both a revenue guidance reduction and an adjusted EBITDA guidance increase, plus specific drivers (U.S. DTC pressure, international distributor inventory management, cost reductions).
Market effects
Signals oxygen concentrator and sleep/airway-adjacent device demand dynamics, especially channel mix shifts between DTC and provider channels.
Highlights international growth strength alongside distributor inventory management issues in the second half.
Mentions China enrollment for Simeox H SCOPE study with analysis expected by end of 2026, relevant to global clinical timelines.
Counterpoint
The revenue guidance cut may be temporary channel normalization, while raised adjusted EBITDA suggests the business can defend earnings even if unit growth slows.
Key entities
- companyInogen, Inc.
Reported Q2 results and updated full-year revenue and adjusted EBITDA guidance; discussed product launches and clinical enrollment.
- personKevin Smith
CEO who discussed market expansion, channel pressures, and scientific credibility initiatives.
- personJason Richardson
CFO who addressed financial performance and guidance drivers.
- personAndy Reding
Appointed COO to oversee operational scale and new product development.
